Statins and SARS-CoV-2 disease: Current concepts and possible benefits.
Diabetes Metab Syndr
; 14(6): 2063-2067, 2020.
Article
in English
| MEDLINE | ID: covidwho-893727
ABSTRACT
BACKGROUND AND AIMS:
Inflammation-mediated tissue injury is the major mechanism involved in the pathogenesis of coronavirus disease 2019 (COVID-2019), caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Statins have well-established anti-inflammatory, anti-thrombotic and immuno-modulatory effects. They may also influence viral entry into human cells.METHODS:
A literature search was done using PubMed and Google search engines to prepare a narrative review on this topic.RESULTS:
Statins interact with several different signaling pathways to exert their anti-inflammatory and vasculoprotective effects. They also variably affect cholesterol content of cell membranes and interfere with certain coronavirus enzymes involved in receptor-binding. Both these actions may influence SARS-CoV-2 entry into human cells. Statins also upregulate expression of angiotensin-converting enzyme 2 receptors on cell surfaces which may promote viral entry into the cells but at the same time, may minimize tissue injury through production of angiotensin [1-7]. The net impact of these different effects on COVID-19 pathogenesis is not clear. However, the retrospective clinical studies have shown that statin use is potentially associated with lower risk of developing severe illness and mortality and a faster time to recovery in patients with COVID-19.CONCLUSIONS:
Early observations suggest beneficial effect of statin use on the clinical outcomes in COVID-19. Prospective randomized studies as well as well-designed laboratory studies are required to confirm these observations and to elucidate the mechanisms of such benefits, if proven.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Inflammation Mediators
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
COVID-19 Drug Treatment
/
Anti-Inflammatory Agents
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Diabetes Metab Syndr
Year:
2020
Document Type:
Article
Affiliation country:
J.dsx.2020.10.021
Similar
MEDLINE
...
LILACS
LIS